Investigation of Kinetic Oscillation Stimulation by the Chordate System S101 in the Treatment of Non Allergic Rhinitis

Nasal Congestion Clinical Trial

— KOSNAR  

Official title:

A Clinical Investigation of Kinetic Oscillation Stimulation by the Chordate System S101 in the Treatment of Non Allergic Rhinitis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03399721
• Other study ID #: PR008
• Status: Completed
• Phase: N/A
• Start date: May 7, 2018
• Est. completion date: September 30, 2022

Study information

• Verified date: July 2022
• Source: Chordate Medical
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an interventional, multicenter, double-blind, placebo-controlled trial in which patients diagnosed with non-allergic rhinitis will be randomized to either intranasal stimulation, or placebo treatment with the Chordate System at two occasions.

Description:

This is a double-blind, placebo-controlled, multi-center study in which patients diagnosed with non-allergic rhinitis will receive intranasal stimulation with the Chordate System at two occasions. Objectives are to evaluate the efficacy of the procedure in reducing disease specific symptoms such as nasal congestion, rhinorrhea, nasal itching and sneezing, but also to investigate the influence on quality of life, safety and tolerability.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 279
• Est. completion date: September 30, 2022
• Est. primary completion date: September 30, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Patients with persistent (>12w) symptoms of non-allergic rhinitis dominated by nasal congestion (± secretion) for an average of at least 1 h per day for at least 5 days during a period of 14 days.

2. Having nasal congestion as major symptom, and a median nasal congestion score of at least 2 (scale 0-3)

3. Male or female 18 - 65 years

4. Judged by the Investigator as suitable for participation in the study without safety concerns based on medical history and physical examination.

5. Willing and able to provide written informed consent prior to participation in the clinical investigation

6. Willing and able to comply with all study related procedures

Exclusion Criteria:

1. Patients with Allergic rhinitis, demonstrated by either positive skin prick test, Phadiatop or RAST during the last year.

2. Ongoing respiratory tract infection including nasal cavity at inclusion

3. Systemic steroid treatment less than 4 weeks before the inclusion in the study

4. Patients with a history of nasal surgery like: septoplasty, cosmetic surgery, conchal surgery or any other nasal surgery except closed reposition for nasal fracture during last year

5. History of frequent nose bleeds or a condition that increases the risk of excessive bleeding

6. Pronounced anterior septal deviation or other significant nasal pathology at endoscopic examination

7. Current malignancy of any kind

8. Known allergy to polyvinylchloride or medicinal liquid paraffin

9. Any disease, condition (medical or surgical) or drug or alcohol abuse which, in the opinion of the investigator, might compromise the study results, or would place the patient at increased risk.

10. Any implant with an electrical and/or neurostimulator device, including but not limited to cardiac pacemaker, defibrillator, vagal neurostimulator, deep brain stimulation, spinal stimulator, bone growth stimulator, or cochlear implant or any other implant in the head-, and neck region.

11. Previous treated with radiation on the face, head or neck regions

12. Female patients who are pregnant or become pregnant at any time from inclusion of the study until end of the 8 week follow-up visit

13. Received study drug in a clinical trial for an investigational drug within the previous 30 days, or 5 half-lives, whichever is longer

Related Conditions & MeSH terms

• Common Cold
• Nasal Congestion
• Non-allergic Rhinitis
• Rhinitis

Intervention

Device:
• Chordate S101
Active treatment: The controller creates air-mediated kinetic oscillations with regulated pressure and frequency during a preset treatment time
• Chordate S101 Placebo
Placebo treatment: Placebo treatment is similar to active treatment, but with no oscillations. It is difficult to discern any difference between active and placebo treatment.

Locations

Country	Name	City	State
Czechia	Charles University Faculty of Medicine in Hradec Králové	Hradec Králové
Czechia	Hospital Pardubice	Pardubice
Czechia	Charles University Motol University Hospital	Prag
Finland	Helsinki University Hospital	Helsinki
Finland	Kuopio University Hospital	Kuopio
Finland	Tampere University Hospital	Tampere
Greece	Aristotle University	Thessaloniki
Italy	Azienda Ospedaliera di Padova	Padova
Italy	Fondazione Policlinico A Gemelli	Rome
Netherlands	Academisch Medisch Centrum Amsterdam	Amsterdam
United Kingdom	University Hospital Birmingham	Birmingham
United Kingdom	James Paget University Hospital	Great Yarmouth
United Kingdom	Guys Hospital, Greate Maze Pond	London

Sponsors (1)

Lead Sponsor	Collaborator
Chordate Medical

Countries where clinical trial is conducted

Czechia,  Finland,  Greece,  Italy,  Netherlands,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Nasal congestion	The primary performance endpoint is the responder rate based on the change in the weekly median nasal congestion score (taken from Total Nasal Symptom Score (TNSS)) from baseline to the 3 month follow-up visit	3 month